These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29741774)

  • 21. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Post-Transplant Lymphoproliferative Disorders.
    Aghsaeifard Z; Alizadeh R
    Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):96-103. PubMed ID: 35927798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.
    Parker A; Bowles K; Bradley JA; Emery V; Featherstone C; Gupte G; Marcus R; Parameshwar J; Ramsay A; Newstead C;
    Br J Haematol; 2010 Jun; 149(5):675-92. PubMed ID: 20408847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives.
    Compagno F; Basso S; Panigari A; Bagnarino J; Stoppini L; Maiello A; Mina T; Zelini P; Perotti C; Baldanti F; Zecca M; Comoli P
    Front Immunol; 2020; 11():567020. PubMed ID: 33042147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Post-transplant lymphoproliferative disorders].
    Forsell S; Lang N
    Rev Med Suisse; 2023 May; 19(827):964-968. PubMed ID: 37195110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-transplant lymphoproliferative disorder after kidney transplantation: time to adopt monitoring of Epstein-Barr virus?
    Biller P; Michaux L; Pauw LD; Camboni A; Mourad M; Kanaan N
    Acta Clin Belg; 2015 Jun; 70(3):218-22. PubMed ID: 25541210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
    Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
    Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttransplantation lymphoproliferative disorders.
    Andreone P; Gramenzi A; Lorenzini S; Biselli M; Cursaro C; Pileri S; Bernardi M
    Arch Intern Med; 2003 Sep; 163(17):1997-2004. PubMed ID: 14504111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-transplant lymphoproliferative disorder.
    Kalinova L; Indrakova J; Bachleda P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Dec; 153(4):251-7. PubMed ID: 20208963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Seville expert workshop for progress in posttransplant lymphoproliferative disorders.
    Glotz D; Chapman JR; Dharnidharka VR; Hanto DW; Castro MC; Hirsch HH; Leblond V; Mehta AK; Moulin B; Pagliuca A; Pascual J; Rickinson AB; Russo FP; Trappe RU; Webster AC; Zuckermann AO; Gross TG
    Transplantation; 2012 Oct; 94(8):784-93. PubMed ID: 22992767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.
    Styczynski J; van der Velden W; Fox CP; Engelhard D; de la Camara R; Cordonnier C; Ljungman P;
    Haematologica; 2016 Jul; 101(7):803-11. PubMed ID: 27365460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.